The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 15)
Improved Biomarkers and Clinical Outcome Measures, 2015
Current methods to evaluate motor impairments in Parkinson's disease rely on subjective examinations. Our team seeks to develop an objective assessment of motor deficits by monitoring natural interactions with a keyboard (on a computer or smart device). This approach provides a window to how the brain behaves during typical daily use of these devices (e.g. writin...
Researchers: Martha L. Gray, PhD
LRRK2 Role in Idiopathic Parkinson's Disease, 2014
Genetic variability in the LRRK2 gene is recognized as one of the most common cause of Parkinson's disease (PD) mainly in the Caucasian, African-Arab, Ashkenazi Jewish and East Asian populations. There is a complete lack of knowledge regarding the role of LRRK2-dependent PD in the Indian population. To understand the role of the LRRK2 locus and its prevalence in the Indian popu...
Research Grant, 2014
The loss of the antioxidant glutathione in the brain of individuals with Parkinson's disease (PD) occurs years before the onset of motor symptoms. Glutathione has been proposed as a neuroprotective therapy for PD for decades, but the therapy has been limited by the lack of oral availability and the invasiveness of intravenous administration. Recently, a Phase I s...
Researchers: Laurie K. Mischley, ND, MPH, PhD(c)
LRRK2 Biology LEAPS, 2012
Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates
Much recent work has suggested that comprehending the biological properties of an enzyme termed LRRK2 that is mutated in about one percent of all Parkinson's disease patients, will be crucial for better understanding of the molecular causes of Parkinson's disease as well as designing new strategies to better treat this condition. Our objective is to deploy the state of the a...
LRRK2 Cohort Working Group, 2012
Two groups have reported a possible association between carrying a LRRK2 mutation and non-skin cancers. In order to determine whether this finding is present in a larger group, or whether specific factors in those populations account for the higher rate of cancer, a larger study from more locations, and with a larger group of Parkinson's subjects and their family...
Researchers: Rachel Saunders-Pullman, MD, MPH, MS